Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 34

1.

Contemporary disengagement from antiretroviral therapy in Khayelitsha, South Africa: A cohort study.

Kaplan SR, Oosthuizen C, Stinson K, Little F, Euvrard J, Schomaker M, Osler M, Hilderbrand K, Boulle A, Meintjes G.

PLoS Med. 2017 Nov 7;14(11):e1002407. doi: 10.1371/journal.pmed.1002407. eCollection 2017 Nov.

2.

Twelve-year mortality in adults initiating antiretroviral therapy in South Africa.

Cornell M, Johnson LF, Wood R, Tanser F, Fox MP, Prozesky H, Schomaker M, Egger M, Davies MA, Boulle A; International Epidemiology Databases to Evaluate AIDS-Southern Africa collaboration.

J Int AIDS Soc. 2017 Sep 25;20(1):21902. doi: 10.7448/IAS.20.1.21902.

3.

Effect of Lopinavir and Nevirapine Concentrations on Viral Outcomes in Protease Inhibitor-experienced HIV-infected Children.

Moholisa RR, Schomaker M, Kuhn L, Castel S, Wiesner L, Coovadia A, Strehlau R, Patel F, Pinillos F, Abrams EJ, Maartens G, McIlleron H.

Pediatr Infect Dis J. 2016 Dec;35(12):e378-e383.

4.

Optimal timing of antiretroviral treatment initiation in HIV-positive children and adolescents: a multiregional analysis from Southern Africa, West Africa and Europe.

Schomaker M, Leroy V, Wolfs T, Technau KG, Renner L, Judd A, Sawry S, Amorissani-Folquet M, Noguera-Julian A, Tanser F, Eboua F, Navarro ML, Chimbetete C, Amani-Bosse C, Warszawski J, Phiri S, N'Gbeche S, Cox V, Koueta F, Giddy J, Sygnaté-Sy H, Raben D, Chêne G, Davies MA; IeDEA West and Southern Africa regional collaborations and COHERE in EuroCoord.

Int J Epidemiol. 2017 Apr 1;46(2):453-465. doi: 10.1093/ije/dyw097.

PMID:
27342220
5.

Mercury and neuromotor function among children in a rural town in Chile.

Ohlander J, Huber SM, Schomaker M, Heumann C, Schierl R, Michalke B, Jenni OG, Caflisch J, Muñoz DM, von Ehrenstein OS, Radon K.

Int J Occup Environ Health. 2016 Jan;22(1):27-35. doi: 10.1080/10773525.2015.1125585. Epub 2016 Feb 1.

6.

Risk Factors for Incident Diabetes in a Cohort Taking First-Line Nonnucleoside Reverse Transcriptase Inhibitor-Based Antiretroviral Therapy.

Karamchand S, Leisegang R, Schomaker M, Maartens G, Walters L, Hislop M, Dave JA, Levitt NS, Cohen K.

Medicine (Baltimore). 2016 Mar;95(9):e2844. doi: 10.1097/MD.0000000000002844.

7.

CD4 count at antiretroviral therapy initiation and the risk of loss to follow-up: results from a multicentre cohort study.

Grimsrud A, Cornell M, Schomaker M, Fox MP, Orrell C, Prozesky H, Stinson K, Tanser F, Egger M, Myer L; International Epidemiologic Databases to Evaluate AIDS Southern Africa Collaboration (IeDEA-SA).

J Epidemiol Community Health. 2016 Jun;70(6):549-55. doi: 10.1136/jech-2015-206629. Epub 2015 Dec 23.

8.

A comparison of death recording by health centres and civil registration in South Africans receiving antiretroviral treatment.

Johnson LF, Dorrington RE, Laubscher R, Hoffmann CJ, Wood R, Fox MP, Cornell M, Schomaker M, Prozesky H, Tanser F, Davies MA, Boulle A; International Epidemiologic Databases to Evaluate AIDS Southern Africa (IeDEA-SA) Collaboration.

J Int AIDS Soc. 2015 Dec 16;18:20628. doi: 10.7448/IAS.18.1.20628. eCollection 2015.

9.

Correction: Risk Factors for Mercury Exposure of Children in a Rural Mining Town in Northern Chile.

Ohlander J, Huber SM, Schomaker M, Heumann C, Schierl R, Michalke B, Jenni OG, Caflisch J, Muñoz DM, von Ehrenstein OS, Radon K.

PLoS One. 2015 Dec 2;10(12):e0144527. doi: 10.1371/journal.pone.0144527. eCollection 2015. No abstract available.

10.

Growth and Mortality Outcomes for Different Antiretroviral Therapy Initiation Criteria in Children Ages 1-5 Years: A Causal Modeling Analysis.

Schomaker M, Davies MA, Malateste K, Renner L, Sawry S, N'Gbeche S, Technau KG, Eboua F, Tanser F, Sygnaté-Sy H, Phiri S, Amorissani-Folquet M, Cox V, Koueta F, Chimbete C, Lawson-Evi A, Giddy J, Amani-Bosse C, Wood R, Egger M, Leroy V; IeDEA West Africa and IeDEA Southern Africa collaboration.

Epidemiology. 2016 Mar;27(2):237-46. doi: 10.1097/EDE.0000000000000412.

11.

Independent predictors of tuberculosis mortality in a high HIV prevalence setting: a retrospective cohort study.

Pepper DJ, Schomaker M, Wilkinson RJ, de Azevedo V, Maartens G.

AIDS Res Ther. 2015 Oct 6;12:35. doi: 10.1186/s12981-015-0076-5. eCollection 2015.

12.

Age in antiretroviral therapy programmes in South Africa: a retrospective, multicentre, observational cohort study.

Cornell M, Johnson LF, Schomaker M, Tanser F, Maskew M, Wood R, Prozesky H, Giddy J, Stinson K, Egger M, Boulle A, Myer L; International Epidemiologic Databases to Evaluate AIDS-Southern Africa Collaboration.

Lancet HIV. 2015 Sep;2(9):e368-75. doi: 10.1016/S2352-3018(15)00113-7. Epub 2015 Aug 4.

13.

Superior virologic and treatment outcomes when viral load is measured at 3 months compared to 6 months on antiretroviral therapy.

Kerschberger B, Boulle AM, Kranzer K, Hilderbrand K, Schomaker M, Coetzee D, Goemaere E, Van Cutsem G.

J Int AIDS Soc. 2015 Sep 23;18:20092. doi: 10.7448/IAS.18.1.20092. eCollection 2015.

14.

Simultaneous Treatment of Missing Data and Measurement Error in HIV Research Using Multiple Overimputation.

Schomaker M, Hogger S, Johnson LF, Hoffmann CJ, Bärnighausen T, Heumann C.

Epidemiology. 2015 Sep;26(5):628-36. doi: 10.1097/EDE.0000000000000334.

15.

Targeted Maximum Likelihood Estimation for Dynamic and Static Longitudinal Marginal Structural Working Models.

Petersen M, Schwab J, Gruber S, Blaser N, Schomaker M, van der Laan M.

J Causal Inference. 2014 Jun 18;2(2):147-185.

16.

Anti-V3/Glycan and Anti-MPER Neutralizing Antibodies, but Not Anti-V2/Glycan Site Antibodies, Are Strongly Associated with Greater Anti-HIV-1 Neutralization Breadth and Potency.

Jacob RA, Moyo T, Schomaker M, Abrahams F, Grau Pujol B, Dorfman JR.

J Virol. 2015 May;89(10):5264-75. doi: 10.1128/JVI.00129-15. Epub 2015 Feb 11.

17.

Is the fetoplacental ratio a differential marker of fetal growth restriction in small for gestational age infants?

Luque-Fernandez MA, Ananth CV, Jaddoe VW, Gaillard R, Albert PS, Schomaker M, McElduff P, Enquobahrie DA, Gelaye B, Williams MA.

Eur J Epidemiol. 2015 Apr;30(4):331-41. doi: 10.1007/s10654-015-9993-9. Epub 2015 Jan 29.

PMID:
25630563
18.

Do increasing rates of loss to follow-up in antiretroviral treatment programs imply deteriorating patient retention?

Johnson LF, Estill J, Keiser O, Cornell M, Moolla H, Schomaker M, Grimsrud A, Davies MA, Boulle A.

Am J Epidemiol. 2014 Dec 15;180(12):1208-12. doi: 10.1093/aje/kwu295. Epub 2014 Nov 15.

19.

Mortality in patients with HIV-1 infection starting antiretroviral therapy in South Africa, Europe, or North America: a collaborative analysis of prospective studies.

Boulle A, Schomaker M, May MT, Hogg RS, Shepherd BE, Monge S, Keiser O, Lampe FC, Giddy J, Ndirangu J, Garone D, Fox M, Ingle SM, Reiss P, Dabis F, Costagliola D, Castagna A, Ehren K, Campbell C, Gill MJ, Saag M, Justice AC, Guest J, Crane HM, Egger M, Sterne JA.

PLoS Med. 2014 Sep 9;11(9):e1001718. doi: 10.1371/journal.pmed.1001718. eCollection 2014 Sep.

20.

Plasma lopinavir concentrations predict virological failure in a cohort of South African children initiating a protease-inhibitor-based regimen.

Moholisa RR, Schomaker M, Kuhn L, Meredith S, Wiesner L, Coovadia A, Strehlau R, Martens L, Abrams EJ, Maartens G, McIlleron H.

Antivir Ther. 2014;19(4):399-406. doi: 10.3851/IMP2749. Epub 2014 Feb 12.

Supplemental Content

Loading ...
Support Center